Iopidine®

Apraclonidine Hydrochloride, the active ingredient in Iopidine®, is a alpha-2 adrenergic agonist presented as an ophthalmic solution for ocular use. It reduces intra‑ocular pressure in patients with ocular hypertension or open‑angle glaucoma. GNH USA supplies Iopidine® as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Iopidine® acts on the ocular pressure regulation pathway and is indicated for several eye‑pressure conditions.

- Ocular hypertension: lowers intra‑ocular pressure to prevent progression to glaucoma. - Open‑angle glaucoma: provides adjunctive therapy when monotherapy does not achieve target pressure. - Post‑operative ocular pressure control: helps manage elevated pressure after eye surgery.

Common Side Effects: - Burning or stinging sensation at the instillation site. - Ocular itching or redness. - Blurred vision shortly after application. - Dry eye sensation. - Mild headache. - Transient conjunctival hyperemia.

Serious or Rare Side Effects: - Allergic reactions such as angio‑edema or severe conjunctivitis. - Significant systemic hypotension leading to dizziness or fainting. - Cardiac arrhythmias in susceptible individuals. - Severe ocular inflammation or uveitis. - Persistent visual disturbances. - Anaphylactic shock (rare).

Before using Iopidine®, consider the following precautions.

- Baseline intra‑ocular pressure assessment: ensure appropriate monitoring. - Cardiovascular disease: use with caution and monitor for systemic hypotensive effects. - Hypersensitivity: avoid if the patient has known allergy to apraclonidine or any excipient. - Severe dry eye: may exacerbate discomfort; evaluate ocular surface health. - Pregnancy and lactation: safety not established; prescribe only if benefits outweigh risks. - Store at room temperature below 25°C: keep in the original container, protect from light and moisture.

Iopidine® may interact with several systemic and ocular agents.

Major Interactions (Avoid): - Systemic antihypertensives (e.g., beta‑blockers, clonidine): increased risk of systemic hypotension. - Other topical ocular hypotensives (e.g., timolol, prostaglandin analogues): additive IOP‑lowering effect, risk of over‑reduction. - Monoamine oxidase inhibitors: potential for exaggerated adrenergic response.

Moderate Interactions (Monitor Closely): - Sympathomimetic eye drops (e.g., phenylephrine): may reduce apraclonidine efficacy. - Non‑steroidal anti‑inflammatory eye drops: may increase ocular irritation. - Systemic sedatives: monitor for dizziness or enhanced hypotensive effect.